150 related articles for article (PubMed ID: 35700815)
1. Prophylactic Administration of Cannabidiol Reduces Microglial Inflammatory Response to Kainate-Induced Seizures and Neurogenesis.
Victor TR; Hage Z; Tsirka SE
Neuroscience; 2022 Sep; 500():1-11. PubMed ID: 35700815
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol inhibits microglia activation and mitigates neuronal damage induced by kainate in an in-vitro seizure model.
Landucci E; Mazzantini C; Lana D; Calvani M; Magni G; Giovannini MG; Pellegrini-Giampietro DE
Neurobiol Dis; 2022 Nov; 174():105895. PubMed ID: 36240948
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
[TBL] [Abstract][Full Text] [Related]
4. Partial protective effects of cannabidiol against PTZ-induced acute seizures in female rats during the proestrus-estrus transition.
Janisset NRLL; Romariz SAA; Hashiguchi D; Quintella ML; Gimenes C; Yokoyama T; Filev R; Carlini E; Barbosa da Silva R; Faber J; Longo BM
Epilepsy Behav; 2022 Apr; 129():108615. PubMed ID: 35217387
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models.
Patra PH; Barker-Haliski M; White HS; Whalley BJ; Glyn S; Sandhu H; Jones N; Bazelot M; Williams CM; McNeish AJ
Epilepsia; 2019 Feb; 60(2):303-314. PubMed ID: 30588604
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures.
Reddy DS; Mbilinyi RH; Ramakrishnan S
Exp Neurol; 2023 Jan; 359():114240. PubMed ID: 36216124
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Golub V; Reddy DS
Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
[TBL] [Abstract][Full Text] [Related]
8. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).
Klein BD; Jacobson CA; Metcalf CS; Smith MD; Wilcox KS; Hampson AJ; Kehne JH
Neurochem Res; 2017 Jul; 42(7):1939-1948. PubMed ID: 28478594
[TBL] [Abstract][Full Text] [Related]
10. The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights.
Lazarini-Lopes W; Do Val-da Silva RA; da Silva-Júnior RMP; Leite JP; Garcia-Cairasco N
Neurosci Biobehav Rev; 2020 Apr; 111():166-182. PubMed ID: 31954723
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.
Jones NA; Glyn SE; Akiyama S; Hill TD; Hill AJ; Weston SE; Burnett MD; Yamasaki Y; Stephens GJ; Whalley BJ; Williams CM
Seizure; 2012 Jun; 21(5):344-52. PubMed ID: 22520455
[TBL] [Abstract][Full Text] [Related]
12. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
13. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone after early-life seizures attenuates increased susceptibility to seizures, seizure-induced microglia activation and neuronal injury later in life.
Fox P; Mithal DS; Somogyi JR; Vien AC; Sanchez RM; Koh S
Neurosci Lett; 2020 May; 728():134953. PubMed ID: 32278942
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol anticonvulsant effect is mediated by the PI3Kγ pathway.
Lima IVA; Bellozi PMQ; Batista EM; Vilela LR; Brandão IL; Ribeiro FM; Moraes MFD; Moreira FA; de Oliveira ACP
Neuropharmacology; 2020 Oct; 176():108156. PubMed ID: 32574650
[TBL] [Abstract][Full Text] [Related]
17. Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats.
Uttl L; Hložek T; Mareš P; Páleníček T; Kubová H
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008517
[TBL] [Abstract][Full Text] [Related]
18. Microglial P2Y12 Receptor Regulates Seizure-Induced Neurogenesis and Immature Neuronal Projections.
Mo M; Eyo UB; Xie M; Peng J; Bosco DB; Umpierre AD; Zhu X; Tian DS; Xu P; Wu LJ
J Neurosci; 2019 Nov; 39(47):9453-9464. PubMed ID: 31597724
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol effect in pentylenetetrazole-induced seizures depends on PI3K.
de Assis Lima IV; Pinto HPP; Bellozi PMQ; da Silva MCM; Vilela LR; Moreira FA; Moraes MFD; de Oliveira ACP
Pharmacol Rep; 2022 Oct; 74(5):1099-1106. PubMed ID: 36112318
[TBL] [Abstract][Full Text] [Related]
20. Seizure-induced increase in microglial cell population in the developing zebrafish brain.
Martins TG; Soliman R; Cordero-Maldonado ML; Donato C; Ameli C; Mombaerts L; Skupin A; Peri F; Crawford AD
Epilepsy Res; 2023 Sep; 195():107203. PubMed ID: 37572541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
